PROMOGRAN PRISMA™ MATRIX

Has What it Takes

PROMOGRAN PRISMA™ MATRIX SUPPORTS GRANULATION AND EPITHELIALIZATION

In a 14-week RCT comparing PROMOGRAN PRISMA® (n=25), with Control (n=15), the number of patients withdrawn from the study due to infection was SIGNIFICANTLY GREATER IN THE CONTROL GROUP

0% VS. 31% (p=0.012) (n=40)

SIGNIFICANTLY GREATER RATE OF WOUND HEALING AT WEEK FOUR

79% VS. 43% for the standard of care
(Improved defined as >50% reduction in wound size)
Don’t Wait—Initiate

Choosing the right dressing has been proven in a PROMOGRAN™ Matrix 6-week RCT to dramatically impact healing time.

**IN A 6-WEEK RCT STUDY**

- **90%** of pressure ulcer wounds completely healed in the **PROMOGRAN™ MATRIX GROUP (n=40)**
- compared to only **70%** in the Control group *(n=40)*

- **69%** shorter mean time to complete healing in the **PROMOGRAN™ MATRIX GROUP**
  - than the Control group (360 days overall hospitalization vs 1,164 days)

Better results with fewer dressing changes

A 12-week RCT of patients with venous leg ulcers *(n=73)*, **47.6% more wounds** *(62% vs 42%, *p*=0.0797)* **healed or improved†** in the PROMOGRAN™ Matrix + compression group than in the Control group (non-adherent dressing + compression). **A significant reduction in wound area** was achieved in the PROMOGRAN™ Matrix + compression group compared to Control *(54.4% vs 36.5%, *p*<0.0001).* *(n=73)*

**REFERENCES**


Follow local institutional protocols for infection control and waste disposal procedures. Local protocols should be based on the applicable federal, state and/or local government environmental regulations.

NOTE: Specific indications, contraindications, warnings, precautions and safety information may exist for Systagenix products. Please consult a healthcare provider and product instructions for use prior to application. Rx only.

Copyright 2017 Systagenix Wound Management, Limited. All rights reserved. All trademarks designated herein are proprietary to Systagenix Wound Management, Limited, its affiliates and/or licensors. LIT # 29-A-326 • PRA000740-R0-US, EN (05/17)